Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 13/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.34 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.34 |
| ▸ | GLRB | P48167 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31663496 | 0.99 | ADORA3 (0.38) | ADORA3ADORA2ACHRNB4CHRNA3RIPK1 | |
| SCHEMBL19224543 | 0.89 | RIPK1 (0.44) | ADORA3ADORA2ACHRNB4CHRNA3RIPK1 | |
| Hydrochloric Acid SCHEMBL19207697 | 0.87 | RIPK1 (0.43) | ADORA3ADORA2ACHRNB4CHRNA3RIPK1 | |
| Hydrochloric Acid SCHEMBL31663495 | 0.87 | RIPK1 (0.43) | ADORA3ADORA2ACHRNB4CHRNA3RIPK1 | |
| SCHEMBL22737084 | 0.83 | CHRNB4 (0.39) | ADORA3ADORA2ACHRNB4CHRNA3RIPK1 | |
| SCHEMBL1561554 | 0.79 | RIPK1 (0.47) | RIPK1 | |
| SCHEMBL1561552 | 0.79 | RIPK1 (0.47) | RIPK1 | |
| SCHEMBL4704981 | 0.79 | RIPK1 (0.47) | RIPK1 | |
| Hydrochloric Acid SCHEMBL2234458 | 0.78 | RIPK1 (0.46) | RIPK1 | |
| Hydrochloric Acid SCHEMBL27177026 | 0.78 | RIPK1 (0.46) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | RIPK1, RIPK3, RIPK4 | ADORA3 3950/4885ADORA2A 4462/4885CHRNB4 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.